Auditoria em Oncologia - Unimed do Brasil
Auditoria em Oncologia - Unimed do Brasil
Auditoria em Oncologia - Unimed do Brasil
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
• Marca<strong>do</strong>res tumorais• CA 125 seria<strong>do</strong>s (pós tratamento)• OS basea<strong>do</strong> > CA 125 ou sintomas• SLD < 4 meses nos testa<strong>do</strong>s• OS 41x 41 meses ns• Rustin GJ, van der Burg ME: A ran<strong>do</strong>mized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level aloneversus delayed treatment based on conventional clinical indicators (MRCOV05/EORTC 55955 trials). J Clin Oncol 27: 18s, 2009(suppl; abstr 1)• PSA não reduz mortalidade (2 estu<strong>do</strong>sran<strong>do</strong>miza<strong>do</strong>s[182+76M testa<strong>do</strong>s])• 1410 rastrea<strong>do</strong>s 9 anos prevenir uma morte.• Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a ran<strong>do</strong>mized prostatecancer• screening trial. N Engl J Med 360:1310-1319,2009• Schro¨ der FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a ran<strong>do</strong>mized• uropean study. N Engl J Med 360:1320-1328, 2009
Change language